ALK-Abelló A/S

CPSE:ALK B 株式レポート

時価総額：DKK 59.6b

ALK-Abelló 将来の成長

Future 基準チェック /36

ALK-Abelló利益と収益がそれぞれ年間14.5%と12.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に19.8% 14.5%なると予測されています。

主要情報

14.5%

収益成長率

14.50%

EPS成長率

Pharmaceuticals 収益成長10.7%
収益成長率12.2%
将来の株主資本利益率19.80%
アナリストカバレッジ

Low

最終更新日27 May 2026

今後の成長に関する最新情報

分析記事 • Nov 15

ALK-Abelló A/S (CPH:ALK B) Just Reported And Analysts Have Been Lifting Their Price Targets

It's been a pretty great week for ALK-Abelló A/S ( CPH:ALK B ) shareholders, with its shares surging 15% to kr.230 in...

Recent updates

ナラティブの更新 • May 29

ALK B: Future Upside Will Come From Allergy Immunotherapy Leadership

Analysts have lifted their price target on ALK-Abelló from DKK 263.33 to DKK 297.50, citing the company’s position as a global leader in allergy immunotherapy and recent supportive research coverage. Analyst Commentary Analysts setting a DKK 305 price target frame ALK-Abelló as a global leader in allergy immunotherapy, and they use that positioning to support a constructive view on the stock’s long term potential.
ナラティブの更新 • Apr 24

ALK B: Future Upside Will Come From Needle Free Anaphylaxis Treatment Adoption

Analysts have nudged their price target for ALK-Abelló to DKK 263.33 from DKK 255, reflecting updated assumptions around slightly adjusted revenue growth, profit margin expectations, and a higher future P/E multiple. What's in the News ALK reported positive topline phase 2 data from the ALLIANCE trial of its once daily sublingual immunotherapy tablet for peanut allergy in patients aged 4 to 65 years, with statistically significant, dose dependent efficacy across multiple tolerated dose and eliciting dose endpoints and a safety profile without treatment related anaphylaxis or serious adverse events (Key Developments).
ナラティブの更新 • Apr 09

ALK B: Future Upside Will Come From Wider Needle Free Anaphylaxis Treatment Adoption

Analysts have adjusted their DKK price targets for ALK-Abelló to reflect updated assumptions for revenue growth of 13.31%, profit margin of 20.66% and a future P/E of 34.79. This suggests a modest recalibration in how the company’s earnings power is being valued.
ナラティブの更新 • Mar 25

ALK B: Future Upside Will Rely On Wider Anaphylaxis Spray Adoption

Analysts have kept their DKK price target for ALK-Abelló broadly unchanged at DKK 255, reflecting stable assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. This signals a steady view on the company’s outlook.
ナラティブの更新 • Mar 11

ALK B: Future Upside Will Rely On Wider Anaphylaxis Treatment Adoption

Analysts have kept their DKK 255.00 price target for ALK-Abelló unchanged, indicating that their views on fair value, discount rate, expected revenue growth, profit margin and future P/E assumptions remain broadly steady. What's in the News ALK-Abelló presented late-breaking data from a 90-participant study comparing needle-free EURneffy nasal adrenaline to injectable auto-injectors for anaphylaxis, with 88% of participants preferring EURneffy, mainly for ease of use, portability and the absence of a needle (AAAAI 2026 Annual Meeting).
ナラティブの更新 • Feb 25

ALK B: Future Returns Will Rely On Expanded Anaphylaxis Indications And Stronger Margins

Analysts have nudged their price target on ALK-Abelló up from DKK 249 to DKK 255, reflecting updated assumptions that combine slightly lower expected revenue growth with a higher projected profit margin and a modestly lower future P/E multiple. What's in the News ALK Abelló issued earnings guidance for 2026, indicating an expectation of continued double digit revenue growth and higher earnings, with revenue projected to grow 11 to 15% in local currencies (company guidance).
ナラティブの更新 • Feb 10

ALK B: Future Returns Will Rely On Expanded Anaphylaxis Reach And Higher 2025 Margins

Analysts have lifted their fair value estimate for ALK-Abelló from DKK 214 to DKK 249, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending EU marketing authorisation for EURneffy 1 mg nasal adrenaline spray for emergency treatment of anaphylaxis in children aged 4 years and older weighing 15 kg to 30 kg.
ナラティブの更新 • Jan 27

ALK B: Future Returns Will Reflect Upgraded 2025 Outlook And Stable Margin Ambitions

Analysts have kept their price target for ALK-Abelló steady at DKK 214. This reflects unchanged assumptions around discount rate, revenue growth, profit margin and future P/E, and indicates that new research has not materially shifted their valuation view.
新しいナラティブ • Jan 23

Pediatric Allergy Tablets And Food Programs Will Drive A Long Runway Of Opportunity

Catalysts About ALK-Abelló ALK Abelló develops and commercialises allergy immunotherapy tablets, injectable and drop therapies, along with anaphylaxis treatments such as Jext and neffy. What are the underlying business or industry changes driving this perspective?
分析記事 • Jan 23

ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
ナラティブの更新 • Jan 12

ALK B: Future Returns Will Reflect Upgraded Outlook And Balanced Margin Prospects

Analysts have trimmed their price target for ALK-Abelló to €214.00 from €219.33, citing updated assumptions that now reflect slightly higher revenue growth, a modestly lower profit margin outlook and a small adjustment to the projected future P/E multiple. What's in the News ALK-Abelló upgraded its earnings guidance for the full year 2025, with expected revenue growth of 13% to 15% in local currencies, compared with a previous range of 12% to 14% (Key Developments).
ナラティブの更新 • Dec 19

ALK B: Future Returns Will Reflect Upgraded Outlook And Solid Margin Prospects

Analysts have modestly lifted their average price target on ALK-Abelló to DKK 219.33, reflecting steady confidence in the company’s unchanged long term growth, margin, and valuation assumptions despite minimal adjustments to underlying model inputs. What's in the News Upgraded 2025 revenue guidance to 13% to 15% growth in local currencies, from 12% to 14%, supported by stronger demand across all regions and product lines (company guidance).
分析記事 • Dec 08

Investors Appear Satisfied With ALK-Abelló A/S' (CPH:ALK B) Prospects

With a price-to-earnings (or "P/E") ratio of 45.8x ALK-Abelló A/S ( CPH:ALK B ) may be sending very bearish signals at...
ナラティブの更新 • Dec 05

ALK B: Future Returns Will Reflect China Alliance And Margin Outlook

Analysts have maintained their DKK 219.33 price target for ALK Abelló, reflecting stable expectations for sustained double digit revenue growth, robust profit margins and a premium future P E multiple. What's in the News Upgraded 2025 guidance, with expected revenue growth raised to 13% to 15% in local currencies, supported by higher treatment volumes across allergy immunotherapy and anaphylaxis products, and an improved projected EBIT margin of about 26% (company guidance).
ナラティブの更新 • Nov 21

ALK B: Improved Margins and China Partnership Will Drive Steady Outlook

Analysts have raised their price target for ALK-Abelló to DKK 219.33 from DKK 196.00. They cite ongoing improvements in profit margins and a slightly higher projected fair value as the reasons for the adjustment.
分析記事 • Nov 15

ALK-Abelló A/S (CPH:ALK B) Just Reported And Analysts Have Been Lifting Their Price Targets

It's been a pretty great week for ALK-Abelló A/S ( CPH:ALK B ) shareholders, with its shares surging 15% to kr.230 in...
ナラティブの更新 • Nov 04

ALK B: Chinese Partnership And Revenue Upside Will Drive Future Opportunities

Analysts have raised their price target for ALK-Abelló from DKK 193 to DKK 196. This change is based on slightly improved revenue growth estimates and valuation adjustments.
分析記事 • Oct 11

Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
ナラティブの更新 • Aug 23

Allergy+ Strategy Will Reach Millions With New Therapies

The increase in ALK-Abelló’s analyst price target is primarily driven by a modest upward revision in consensus revenue growth forecasts, while net profit margins remain steady, resulting in a new fair value estimate of DKK192.33 per share. What's in the News ALK-Abelló raised its 2025 revenue growth guidance to 12-14% (from 9-13%) in local currencies, supported by strong adrenaline autoinjector and tablet sales in Europe and North America, and will allocate additional funds to strategic growth investments.
分析記事 • Jul 23

ALK-Abelló A/S' (CPH:ALK B) Popularity With Investors Is Clear

With a price-to-earnings (or "P/E") ratio of 44.9x ALK-Abelló A/S ( CPH:ALK B ) may be sending very bearish signals at...
分析記事 • Jun 17

ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
User avatar
新しいナラティブ • Dec 11

Allergy+ Strategy And Neffy Nasal Spray Will Ignite Revenue Growth And Boost Earnings

The Allergy+ strategy and neffy nasal spray deal are expected to create new revenue streams and drive growth from 2025 onward.

業績と収益の成長予測

CPSE:ALK B - アナリストの将来予測と過去の財務データ ( )DKK Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20289,3291,8671,4481,9045
12/31/20278,2591,6441,2441,6965
12/31/20267,2731,4451,0761,5415
3/31/20266,5611,2801,7962,189N/A
12/31/20256,3121,1971,4571,817N/A
9/30/20256,0781,1012181,548N/A
6/30/20255,861999701,380N/A
3/31/20255,708937181,319N/A
12/31/20245,537815-901,213N/A
9/30/20245,3837857771,086N/A
6/30/20245,1806907241,046N/A
3/31/20244,941555449796N/A
12/31/20234,824486288667N/A
9/30/20234,72842417426N/A
6/30/20234,680359-76343N/A
3/31/20234,59033590479N/A
12/31/20224,51133563416N/A
9/30/20224,361333149489N/A
6/30/20224,227318163493N/A
3/31/20224,050255152432N/A
12/31/20213,916219205468N/A
9/30/20213,808112273505N/A
6/30/20213,65255158358N/A
3/31/20213,55666147358N/A
12/31/20203,4912579301N/A
9/30/20203,3834387298N/A
6/30/20203,35049149353N/A
3/31/20203,363-9-14172N/A
12/31/20193,274-50N/A132N/A
9/30/20193,178-183N/A59N/A
6/30/20193,100-200N/A-54N/A
3/31/20193,030-149N/A-27N/A
12/31/20182,915-170N/A-95N/A
9/30/20182,891-183N/A-223N/A
6/30/20182,897-152N/A-214N/A
3/31/20182,873-136N/A-386N/A
12/31/20172,910-158N/A-387N/A
9/30/20172,90137N/A-278N/A
6/30/20172,86476N/A-146N/A
3/31/20172,946149N/A206N/A
12/31/20163,005270N/A405N/A
9/30/20162,938373N/A492N/A
6/30/20162,975396N/A458N/A
3/31/20162,767378N/A312N/A
12/31/20152,569344N/A183N/A
9/30/20152,494221N/A153N/A
6/30/20152,349185N/A136N/A

アナリストによる今後の成長予測

収入対貯蓄率: ALK Bの予測収益成長率 (年間14.5% ) は 貯蓄率 ( 2% ) を上回っています。

収益対市場: ALK Bの収益 ( 14.5% ) はDanish市場 ( 9% ) よりも速いペースで成長すると予測されています。

高成長収益: ALK Bの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: ALK Bの収益 ( 12.2% ) Danish市場 ( 3.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: ALK Bの収益 ( 12.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ALK Bの 自己資本利益率 は、3年後には低くなると予測されています ( 19.8 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/11 02:22
終値2026/06/11 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

ALK-Abelló A/S 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9

アナリスト機関
null nullABG Sundal Collier
Mads Brinkmann AndersenBerenberg
Jesper IlsoeCarnegie Investment Bank AB